http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6905691-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b0f26bec9a02dee5329300a5ae7d0370 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-542 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-522 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0275 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N1-20 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-20 |
| filingDate | 2000-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2005-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9cdf74763acca2b87a484733c03509e3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8001958b7c8c663e4439522a151a739b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1700c9e034e87d63951abbc37505aff9 |
| publicationDate | 2005-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-6905691-B1 |
| titleOfInvention | Vaccines containing attenuated bacteria |
| abstract | The invention relates to a vaccine comprising a bacterium attenuated by a non-reverting mutation in a gene encoding a protein which promotes folding of extracytoplasmic proteins. Such mutations were initially identified as being useful in vaccines from a bank of randomly inserted, transposon mutants in which attenuation was determined as a reduction in virulence of the organism in the mouse model of infection. Site directed mutation of the gene results in a strain which shows at least 4 logs of attenuation when delivered both orally and intravenously. Animals vaccinated with such a strain are protected against subsequent challenge with the parent wild type strain. Finally, heterologous antigens such as the non-toxic and protective, binding domain from tetanus toxin, fragment C, can be delivered via the mucosal immune system using such strains of bacteria. This results in the induction of a fully protective immune response to subsequent challenge with native tetanus toxin. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008274136-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7794730-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11406702-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10973908-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012123269-A1 |
| priorityDate | 1997-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 162.